<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00545857</url>
  </required_header>
  <id_info>
    <org_study_id>20064114</org_study_id>
    <nct_id>NCT00545857</nct_id>
  </id_info>
  <brief_title>Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus</brief_title>
  <official_title>Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to examine the effect of pioglitazone on the course of new onset type 1 diabetes
      mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thiazolidinediones have been shown to reduce the development of diabetes mellitus in animal
      models of type 1 diabetes and to reduce the death of beta cells (cells that make insulin) in
      petri dishes. Pioglitazone is a thiazolidinedione currently approved for the treatment of
      type 2 diabetes. This study explores the question of whether pioglitazone can preserve beta
      cell function in patients with recently diagnosed type 1 diabetes mellitus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-peptide response to a Sustacal meal</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin requirement</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>Pioglitazone daily; dose varies with size</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_label>Placebo control</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_label>Placebo control</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 1 diabetes mellitus diagnosed within 4 months

          -  Age &gt; 6 years of age

          -  Ability to swallow capsule

          -  Signed informed consent / assent

        Exclusion Criteria:

          -  Other illnesses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas A Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York, Stony Brook</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas A. Wilson, MD</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2007</study_first_posted>
  <last_update_submitted>May 30, 2012</last_update_submitted>
  <last_update_submitted_qc>May 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stony Brook University</investigator_affiliation>
    <investigator_full_name>Thomas A. Wilson</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Type 1 diabetes</keyword>
  <keyword>Insulin dependent diabetes</keyword>
  <keyword>Juvenile onset diabetes</keyword>
  <keyword>pioglitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

